by Grit Kienzlen
RESEARCH ROUND-UP	Concern over BRCA2 patent Email: Grit Kienzlen - grit.kienzlen@web.de News from The Scientist 2005, 6(1):20050516-01 Published   16 May 2005

Some Jewish women in Europe could face discrimination in access to breast cancer diagnosis as a result of changes made to a patent for the gene BRCA2, owned by Utah-based firm Myriad Genetics, geneticists said at a meeting this week. They said that the changes could mean that women seeking testing would have to disclose whether they were Ashkenazi Jews, and might preclude testing in countries without testing licenses.

(continued >>)

To continue reading this full article, you must be a subscriber to The Scientist.

You are only a few minutes away from unlimited access.

If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.

Subscribe to The Scientist to get unlimited access to our premium content

Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95.  Subscribe now.

The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.